The role of intravenous iron in anemia management and transfusion avoidance. (abre uma nova janela)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Fonte‎: Transfusion 2008;48(5):988-1000.

Indexado‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (abre uma nova janela)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (abre uma nova janela)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Fonte‎: BJU Int 2011;108(10):1582-7.

Indexado‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (abre uma nova janela)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (abre uma nova janela)

Lepor H, Lipkin M, Slova D.

Fonte‎: Urology 2010;75(6):1424-8.

Indexado‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (abre uma nova janela)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (abre uma nova janela)

Nieder AM, Rosenblum N, Lepor H.

Fonte‎: Urology 2001;57(4):737-41.

Indexado‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (abre uma nova janela)